Japanese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Impact of an Intensified Thromboprofylaxis Protocol in COVID-19

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
リンクがクリップボードに保存されます
状態完了
スポンサー
Jessa Hospital

キーワード

概要

The aim of this study is to investigate and compare the mortality, the incidence of DVT and the incidence of kidney and liver failure in patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol on 31st of March 2020. Patients in the before group are admitted at the ICU from 13/3/2020-30/3/2020 and patients in the after group are admitted to the ICU from 31/3 until 20/4/2020.

説明

Background Patients admitted to the Intensive Care Unit (ICU) are known to be at risk for thrombo-embolic events. Virchow's triad describes the major risk factors in three categories: venous stasis, vessel injury and activation of blood coagulation. A prolonged mechanical ventilation together with the hemodynamic effects of this ventilation with a high positive and expiratory pressure (PEEP), the presence of central venous catheters, the immobilization of these patients and the presence of obesity or other comorbidities can attribute to the occurrence of a deep venous thrombosis (DVT) in patients admitted at ICU. The incidence of DVT during ICU stay has been reported between 5 and 15%.

On the 13th of March, the first COVID-19 patient was admitted at the ICU at the Jessa Hospital. Within a few days, the admissions at our COVID-19 unit grew exponential. In these difficult time, research concerning COVID-19 has been performed indicating the COVID-19 virus induces a hyper-inflammatory state. It has been suggested that systemic inflammation induces endothelial injury. This will activate the coagulation cascade and impair fibrinolysis with disruption of endothelial barrier, and loss of physiologic antithrombotic factors which may elevated the risk for DVTs significantly. Up to now, there is still no causal treatment for COVID-19. The current management of COVID-19 is mainly supportive i.e. a prolonged inflammatory status and a prolonged risk for VTE.

We have shown in a previous cross sectional study that the prevalence of deep venous thrombosis (DVT) in critically ill ICU patients with COVID-19 treated with a prophylactic dose of low molecular weight heparin (LMWH) is more than 60% (submitted manuscript). Consequently, the risk of VTE complications in this patient group is very high. In the light of these findings, an intensified thromboprofylaxis protocol was applied in critically ill ICU patients with COVID-19 at our ICU units since 31st of March 2020.

Aim The aim of this study is to investigate and compare the mortality, the incidence of DVT and the incidence of kidney and liver failure in patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol on 31st of March 2020. Patients in the before group are admitted at the ICU from 13/3/2020-30/3/2020 and patients in the after group are admitted to the ICU from 31/3 until 20/4/2020.

Design This is a retrospective, longitudinal, before-after controlled study investigating the mortality, the incidence of DVT and the incidence of kidney and liver failure in COVID-19 patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol.

Outcome measures The primary endpoint of this retrospective study is to investigate the mortality in critically ill ICU patients before and after the implementation of the intensified thromboprofylaxis protocol in our hospital.

Secondary endpoints are the incidence of DVTs with the number and locations of these thromboses, the incidence of kidney failure and the incidence of liver failure in COVID-19 patients admitted to the ICU before and after the implementation of the thromboprofylaxis protocol.

Additional data collection

Additional collected parameters are listed below and are collected as a standard-of-care in our hospital:

- Demographics: i.e age, gender, BMI, Apache II score (to predict mortality)

- Comorbidities: smoking, obesity, hypertension, diabetes, cardiovascular disease, respiratory disease, malignancies, renal failure (AKI), liver failure, gastrointestinal disease, neurological conditions, mental state, other

- Symptoms at the time of admission to ICU: i.e fever, body temperature, dyspnoea, headache, diarrhea etc…

- Laboratory results of all standard parameters measured

- Treatment: antiviral agents, antibiotics, etc…

- Complications: shock, heart failure, sepsis, stroke, etc…

- Ventilation: method, PEEP, FiO2, P/F ratio ..

- SOFA score (Sequential Organ Failure Assessment)

- Radiological findings: pneumonia, ground-glass opacity..

日付

最終確認済み: 04/30/2020
最初に提出された: 05/15/2020
提出された推定登録数: 05/15/2020
最初の投稿: 05/18/2020
最終更新が送信されました: 05/15/2020
最終更新日: 05/18/2020
実際の研究開始日: 05/03/2020
一次完了予定日: 05/14/2020
研究完了予定日: 05/14/2020

状態または病気

COVID19
Thromboembolism

介入/治療

Other: After or intervention group

Other: Before or control group

段階

-

アームグループ

介入/治療
Before or control group
All patients admitted to ICU from March 13th 2020 until March 30th 2020 received routine low dose pharmacological VTE prophylaxis
Other: Before or control group
This protocol contains a routine low dose pharmacological venous thromboembolism (VTE) prophylaxis with LMWH
After or intervention group
On March 31th 2020 an individualised, more aggressive thromboprophylaxis protocol was implemented. This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity
Other: After or intervention group
This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity

適格基準

研究の対象となる年齢 18 Years に 18 Years
研究に適格な性別All
サンプリング方法Probability Sample
健康なボランティアを受け入れる番号
基準

Inclusion Criteria:

- All adult COVID19+ patients admitted to the ICU from 13th of March until 20th of April 2020.

Exclusion Criteria:

- Patients younger than 18 years old.

結果

主な結果の測定

1. 2 week mortality [2 weeks after admission at ICU]

mortality was assessed in all COVID 19 patients admitted to the ICU

二次的な結果の測定

1. incidence of venous thromboembolism [during ICU stay up till 3th of May 2020]

the incidence of venous thromboembolism was evaluated in all COVID 19 patients admitted to the ICU

2. 1 week mortality [1 week after admission at ICU]

mortality was assessed in all COVID 19 patients admitted to the ICU

3. 3 week mortality [3 weeks after admission at ICU]

mortality was assessed in all COVID 19 patients admitted to the ICU

4. 1 month mortality [1 month after admission at ICU]

mortality was assessed in all COVID 19 patients admitted to the ICU

5. incidence of kidney failure [during ICU stay up till 3th of May 2020]

incidence of acute kidney failure in all COVID 19 patients admitted to the ICU

6. incidence of continuous renal replacement therapy (CRRT) [during ICU stay up till 3th of May 2020]

incidence of continuous renal replacement therapy (CRRT) in all COVID 19 patients admitted to the ICU

7. lowest PaO2/FiO2 (P/F) ratio [during ICU stay up till 3th of May 2020]

evaluation of the lowest P/F ratio in all COVID 19 patients admitted to the ICU

8. highest Sequential Organ Failure Assessment (SOFA) score [during ICU stay up till 3th of May 2020]

evaluation of the highest SOFA score in all COVID 19 patients admitted to the ICU

9. length of stay [during ICU and hospital stay up till 3th of May 2020]

evaluation of the length of stay in ICU and hospital of all COVID 19 patients admitted to the ICU

10. highest bilirubin [during ICU stay up till 3th of May 2020]

evaluation of the highest bilirubine level in all COVID 19 patients admitted to the ICU

11. highest ( AST [during ICU stay up till 3th of May 2020]

evaluation of the highest AST level in all COVID 19 patients admitted to the ICU

12. highest Aspartaat-Amino-Transferase (ALT) [during ICU stay up till 3th of May 2020]

evaluation of the highest ALT level in all COVID 19 patients admitted to the ICU

Facebookページに参加する

科学に裏打ちされた最も完全な薬草データベース

  • 55の言語で動作します
  • 科学に裏打ちされたハーブ療法
  • 画像によるハーブの認識
  • インタラクティブGPSマップ-場所にハーブをタグ付け(近日公開)
  • 検索に関連する科学出版物を読む
  • それらの効果によって薬草を検索する
  • あなたの興味を整理し、ニュース研究、臨床試験、特許について最新情報を入手してください

症状や病気を入力し、役立つ可能性のあるハーブについて読み、ハーブを入力して、それが使用されている病気や症状を確認します。
*すべての情報は公開された科学的研究に基づいています

Google Play badgeApp Store badge